The present invention provides a polymer replica of a target molecule, the polymer replica being capable of accurately inheriting surface information possessed by the target molecule in a molecular imprinting technique. A polymer replica of a target substance, the target substance having multiple types of binding groups including at least a binding group BG1 and a binding group BG2 on the surface, wherein: the polymer replica is configured from a second molecularly imprinted polymer having, as a template, a first molecularly imprinted polymer having the target substance as a template; the polymer replica has on the surface thereof at least a binding group bg1 at a position corresponding to the position of binding group BG1 and a binding group bg2 at a position corresponding to the position of the binding group BG2 on the surface of the target substance; and the polymer replica of the target substance can be used as a template during synthesis of a molecularly imprinted polymer having a specific recognition site for the target substance because the polymer replica accurately inherits the surface information possessed by the target molecule.

Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.

Provided are the use of cereblon (CRBN) as a biomarker for diagnosis of hepatocellular carcinoma and novel monoclonal antibodies specific to CRBN. More specifically, provided are a composition and a kit for diagnosing or predicting the prognosis of hepatocellular carcinoma by using CRBN as a biomarker for diagnosis of hepatocellular carcinoma, an information providing method for diagnosing or predicting the prognosis of hepatocellular carcinoma, two novel monoclonal antibodies binding specifically to CRBN, and hybridoma cells producing the same. The expression level difference of CRBN protein allows patients with hepatocellular carcinoma to be diagnosed early and indicates better predictive capabilities than the presence or absence of microvascular invasion, which was an important factor in predicting a prognosis of hepatocellular carcinoma in prior art, and thus can be expected to be used as a diagnostic marker to diagnose hepatocellular carcinoma and to evaluate a prognosis after hepatic resection.

The present disclosure relates to methods for predicting time-to-delivery in pregnant women. The methods include predicting that a pregnant woman will deliver within a predetermined time frame if PAMG-1 is determined to be present at a level above a predetermined detection threshold in a vaginal fluid sample obtained from the pregnant woman. Also provided are methods for determining a patient's risk of preterm labor and/or spontaneous rupture of the chorioamniotic membrane.

Disclosed herein are methods, kits, tests, and systems for detecting, predicting, monitoring, or ruling out preeclampsia in pregnant women. Also provided herein are novel diagnostic markers, methods of data analysis, assay formats, and kits employing such markers to improve one or more characteristics of a test for identifying or ruling out preeclampsia based on biomarkers from patient samples.

Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.

A system for providing colorimetric and ratiometric comparison and quantification for medical test results, comprising a testing device including an alignment target and including a plurality of immunoassay test strips, the plurality of immunoassay test strips each including a test line and a control line, and a colorimetry device configured to operate with a mobile device, the mobile device including a camera and a software application stored thereon, wherein the software application provides executable instructions to detect color properties of a color of the test line and a color of a control line of at least one of the plurality of immunoassay test strips, determine a risk value for each of at least one disease risks tested using the biologic sample, wherein the risk value is a rating determined from the color properties of the color of the test line, and provide medical test results based on the risk value.

A method of making a noninvasive molecular control and analysis is described. The method of making the noninvasive molecular control includes, predetermining a positive control for a condition of interest, selecting a cell line with a control marker for the condition of interest, amplifying release of cfDNA from the selected cell line, isolating the released cfDNA from the selected cell line, quantifying the control marker from the isolated cfDNA, determining a volume of the control marker for addition to an isolated control plasma, isolating the control plasma from a control sample, treating the isolated control plasma with a control stabilizer, determining a volume of the control plasma to add to the volume of control marker, combining the volume of the control marker with the isolated control plasma, and analyzing a sample against the noninvasive molecular control to determine the presence or absence of a condition of interest.

Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.

The present disclosure relates to methods for predicting time-to-delivery in pregnant women. The methods include predicting that a pregnant woman will deliver within a predetermined time frame if PAMG-1 is determined to be present at a level above a predetermined detection threshold in a vaginal fluid sample obtained from the pregnant woman. Also provided are methods for determining a patient's risk of preterm labor and/or spontaneous rupture of the chorioamniotic membrane.